Phenothiazine

Phenothiazine

SCHEMBL29352248

c1ccc2c(c1)Nc1ccccc1S2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOX1 Q9Y5S8 10/20 1.00
MAPT P10636 7/20 1.00
GAA P10253 6/20 1.00
MEN1 O00255 3/20 1.00
KMT2A Q03164 3/20 1.00
BCHE P06276 3/20 1.00
ACHE P22303 3/20 1.00
SNCA P37840 3/20 1.00
ALOX15 P16050 3/20 1.00
TDP1 Q9NUW8 2/20 1.00
CYP1A2 P05177 2/20 1.00
POLB P06746 1/20 1.00
CYP3A4 P08684 1/20 1.00
ADORA3 P0DMS8 1/20 1.00
ALOX12 P18054 1/20 1.00
MAOA P21397 1/20 1.00
CNR1 P21554 1/20 1.00
PTGS1 P23219 1/20 1.00
SLC6A2 P23975 1/20 1.00
HTR2C P28335 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenothiazine SCHEMBL9114 1.00 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL29349533 1.00 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL2504207 1.00 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL6315328 1.00 NOX1 (1.00) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL23683396 0.97 NOX1 (0.94) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL22467844 0.97 NOX1 (0.94) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL1470980 0.97 NOX1 (0.94) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL22467847 0.97 NOX1 (0.94) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL21635186 0.97 NOX1 (0.94) NOX1MAPTGAAMEN1KMT2A
Phenothiazine SCHEMBL1470990 0.97 NOX1 (0.94) NOX1MAPTGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1786 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4424802-B1 LUBRICANT COMPOSITION NOF CORP (JP) 2026-05-27 EP claimed
WO-2026104576-A1 COMPOSITION COMPRISING PRE-POLYMER WITH IMPROVED MECHANICAL PROPERTIES TISSIUM SA (FR) 2026-05-21 WO claimed
CN-122029144-A Apparatus and condensation method 三菱化学英国有限公司 2026-05-12 CN claimed
EP-3762382-B1 MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2026-04-29 EP claimed
EP-4543865-B1 PROCESS FOR PREPARING SOLKETAL ACRYLATE BY TRANSESTERIFICATION BASF SE (DE) 2026-04-29 EP claimed
US-20260092030-A1 IMPROVED PROCESS FOR PRODUCING HIGH-PURITY BUTYL ACRYLATE ARKEMA FRANCE (FR) 2026-04-02 US claimed
EP-4267659-B1 SILOXANE-IMIDE COPOLYMER AND ADDITION CURABLE COMPOSITION COMPRISING SAME MOMENTIVE PERFORMANCE MAT INC (US) 2026-03-25 EP claimed
EP-4055088-B1 COMPOSITION AND METHOD FOR MANUFACTURING RESINS CAMBIUM BIOMATERIALS INC (US) 2026-03-25 EP claimed
EP-4396191-B1 COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING JAGUAHR THERAPEUTICS PTE LTD (SG) 2026-02-18 EP claimed
EP-4165465-B1 SYSTEMS AND METHODS FOR INDICATING THE TIME ELAPSED SINCE THE OCCURRENCE OF A TRIGGERING EVENT JOHNSON & JOHNSON VISION CARE (US) 2026-02-18 EP claimed
CN-110099891-B Method for separating pure 2-ethylhexyl acrylate or pure 2-propylheptyl acrylate from corresponding crude alkyl acrylate by distillation 巴斯夫欧洲公司 2022-06-10 CN claimed
EP-3663288-B1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO (JP) 2022-06-08 EP claimed
EP-1464322-B2 Use of compositions containing a chosen fluorescent dye and a chosen amphoteric or nonionic surfactant for dyeing human kerateous fibres with a bleaching effect OREAL (FR) 2022-06-01 EP claimed
EP-3778578-B1 IMMUNOPROTEASOME INHIBITOR ANALOGS FOR TREATING INFLAMMATORY DISEASES UNIV CALIFORNIA (US) 2022-05-04 EP claimed
CN-114249760-A Synthesis and application of fluorescent probe capable of simultaneously distinguishing hypochlorous acid and hydrogen peroxide in three channels 湖南师范大学 2022-03-29 CN claimed
EP-3648877-B1 PROCESS FOR CONTINUOUS DISSOLUTION OF A SOLID IN A REACTION MEDIUM EVONIK OPERATIONS GMBH (DE) 2022-03-16 EP claimed
EP-3613727-B1 PREPARATION METHOD FOR CO-PRODUCING ACRYLAMIDE AND FORMAMIDE COMPOUNDS SHENZHEN UV CHEM TECH INC (CN) 2022-03-16 EP claimed
EP-3439077-B1 LITHIUM-IODINE ELECTROCHEMICAL CELLS EXHIBITING LOW DISCHARGE IMPEDANCE GREATBATCH LTD (US) 2022-02-23 EP claimed
CN-110573565-B Packaging composition 株式会社LG化学 2022-02-11 CN claimed
EP-3724174-B1 METHOD FOR THE PRODUCTION OF GLYCERINE CARBONATE METHACRYLATE BASF SE (DE) 2022-02-09 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092030-A1 IMPROVED PROCESS FOR PRODUCING HIGH-PURITY BUTYL ACRYLATE ACR, ADH1C, RTCB NOX1 2409/4885MAPT 1794/4885GAA 1694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.